中枢神经系统生物标记市场规模、份额和成长分析（按类型、应用、最终用户和地区划分）—产业预测，2026-2033年

全球中枢神经系统生物标记市场规模预计在 2024 年达到 60.5 亿美元，从 2025 年的 65.4 亿美元成长到 2033 年的 122 亿美元，在预测期（2026-2033 年）内复合年增长率为 8.1%。

受人口结构和生活方式变化的影响，神经系统疾病发病率不断上升，推动了全球中枢神经系统生物标记市场显着成长。这种盛行率的激增促使人们对精准早期诊断的需求日益增长，并促进了基于生物标记的诊断技术的应用。研发领域的创新不断加深我们对中枢神经系统疾病分子和遗传基础的理解，催生了灵敏度和特异性更高的新型生物标记。此外，个人化医疗的兴起使得生物标记分析对于优化患者选择和治疗监测至关重要。儘管面临标准化需求、监管障碍以及中枢神经系统疾病固有的复杂性等挑战，中枢神经系统生物标记在推进神经科学领域的治疗策略和药物研发方面仍然发挥关键作用。

全球中枢神经系统生物标记市场驱动因素

包括阿兹海默症、帕金森氏症和多发性硬化症在内的神经系统疾病发病率不断上升，显着推动了中枢神经系统（CNS）生物标记市场的成长。随着这些疾病的日益普遍，对准确及时诊断的需求也日益迫切，促使医疗服务提供者和研究人员寻求基于生物标记的创新诊断解决方案。对神经系统疾病早期检测和有效管理的日益重视，推动了对先进生物标记的需求，最终重塑了中枢神经系统诊断市场的模式。此外，对改善患者预后的追求也进一步增强了对这些关键诊断工具的依赖。

限制全球中枢神经系统生物标记市场的因素

由于中枢神经系统疾病的复杂性和多面性，全球中枢神经系统生物标记市场面临严峻挑战。这种复杂性使得识别能够真正反映疾病潜在机制的可靠且特异性的生物标记变得困难。此外，不同中枢神经系统疾病之间的差异也使得通用生物标记的开发更加复杂，因为它们可能无法与这些疾病的各种临床表现和病理过程完全对应。因此，寻找能够有效指导诊断和治疗的精准生物标记仍然是该市场的主要障碍，阻碍了发展和创新。

全球中枢神经系统生物标记市场趋势

全球中枢神经系统生物标记市场正经历一场变革性的演变，而这主要得益于技术的显着进步。高通量筛检技术、次世代定序和先进的成像方式等创新技术正在提高生物标记检测的灵敏度和特异性。这些进步不仅提高了中枢神经系统疾病诊断和监测的准确性，也促进了个人化医疗的实现。由此产生的对可靠、精准生物标记的需求，刺激了生物技术公司、研究机构和医疗服务提供者之间的投资与合作，从而推动了这个充满活力的市场的成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管环境
• 专利分析

全球中枢神经系统生物标记市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 安全生物标记
• 疗效生物标记
• 检验的生物标记

全球中枢神经系统生物标记市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 诊断
  • 阿兹海默症
  • 帕金森氏症
  • 多发性硬化症
  • 中风
• 药物发现与开发
  • 临床前试验
  • 临床试验
• 个人化医疗
  • 基因生物标誌物
  • 蛋白质体学生物标誌物
  • 代谢体学物标誌物

全球中枢神经系统生物标记市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 诊断检查室
• 研究所
• 生物製药公司

全球中枢神经系统生物标记市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• F. Hoffmann-La Roche Ltd（Switzerland）
• Novartis AG（Switzerland）
• Siemens Healthineers AG（Germany）
• Thermo Fisher Scientific Inc.（USA）
• Abbott Laboratories（USA）
• Merck KGaA（Germany）
• Eurofins Scientific（Luxembourg）
• Charles River Laboratories International, Inc.（USA）
• PerkinElmer Inc.（USA）
• Bio-Rad Laboratories, Inc.（USA）
• QIAGEN NV（Netherlands）
• Axon Neuroscience SE（Slovakia）
• Alector Inc.（USA）
• Oryzon Genomics SA（Spain）
• Banyan Biomarkers Inc.（USA）
• Avacta Group PLC（UK）
• Geno Technology Inc.（USA）
• Anavex Life Sciences Corp.（USA）
• Alseres Pharmaceuticals Inc.（USA）
• Aposense Ltd.（Israel）

结论与建议

Global Central Nervous System Biomarkers Market size was valued at USD 6.05 Billion in 2024 and is poised to grow from USD 6.54 Billion in 2025 to USD 12.2 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).

The global market for CNS biomarkers is witnessing substantial growth, fueled by the rising incidence of neurological disorders, influenced by demographic shifts and lifestyle changes. This surge in prevalence prompts a heightened demand for precision in early diagnosis, fostering the use of biomarker-based diagnostic technologies. Innovations in research are enhancing our comprehension of the molecular and genetic underpinnings of CNS conditions, leading to the emergence of novel biomarkers that improve sensitivity and specificity. Furthermore, the shift towards personalized medicine necessitates biomarker analysis for optimized patient selection and treatment monitoring. Despite challenges such as the need for standardization, regulatory hurdles, and the intrinsic complexity of CNS disorders, CNS biomarkers remain pivotal in advancing therapeutic strategies and drug development in neuroscience.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Central Nervous System Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Central Nervous System Biomarkers Market Segments Analysis

Global Central Nervous System Biomarkers Market is segmented by Type, Application, End-User and region. Based on Type, the market is segmented into Safety Biomarkers, Efficacy Biomarkers and Validation Biomarkers. Based on Application, the market is segmented into Diagnostics, Drug Discovery & Development and Personalized Medicine. Based on End-User, the market is segmented into Hospitals, Diagnostic Laboratories, Research Institutes and Biopharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Central Nervous System Biomarkers Market

The increasing incidence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, significantly propels the growth of the Central Nervous System (CNS) biomarkers market. As these conditions become more widespread, the urgent need for precise and timely diagnoses intensifies, driving healthcare providers and researchers to seek innovative biomarker-based diagnostic solutions. This heightened focus on early detection and effective management of neurological diseases fosters a growing demand for advanced biomarkers, ultimately shaping the landscape of the CNS diagnostics market. Moreover, the quest for improved patient outcomes further amplifies the reliance on these critical diagnostic tools.

Restraints in the Global Central Nervous System Biomarkers Market

The Global Central Nervous System Biomarkers market faces significant challenges due to the intricate and multifaceted nature of CNS disorders. This complexity makes it difficult to pinpoint reliable and specific biomarkers that truly represent the underlying disease mechanisms. Furthermore, the variability among different CNS conditions complicates the development of universal biomarkers, as they may not uniformly correlate with the diverse clinical manifestations and pathological processes of these disorders. As a result, the quest for accurate biomarkers that can effectively guide diagnosis and treatment remains a significant obstacle within this market, hindering progress and innovation.

Market Trends of the Global Central Nervous System Biomarkers Market

The Global Central Nervous System Biomarkers market is experiencing a transformative evolution driven by significant technological advancements. Innovations like high-throughput screening techniques, next-generation sequencing, and sophisticated imaging modalities are enhancing the sensitivity and specificity of biomarker detection. This surge in technology not only improves the accuracy of diagnosing and monitoring central nervous system disorders but also facilitates personalized medicine approaches. As a result, the demand for reliable and precise biomarkers is rising, attracting investment and fostering collaborations among biotech firms, research institutions, and healthcare providers, ultimately propelling growth in this dynamic market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Central Nervous System Biomarkers Market Size by Type & CAGR (2026-2033)

• Market Overview
• Safety Biomarkers
• Efficacy Biomarkers
• Validation Biomarkers

Global Central Nervous System Biomarkers Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diagnostics
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Stroke
• Drug Discovery & Development
  • Preclinical Studies
  • Clinical Trials
• Personalized Medicine
  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Metabolomic Biomarkers

Global Central Nervous System Biomarkers Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Biopharmaceutical Companies

Global Central Nervous System Biomarkers Market Size & CAGR (2026-2033)

• North America (Type, Application, End-User)
  • US
  • Canada
• Europe (Type, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axon Neuroscience SE (Slovakia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alector Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oryzon Genomics S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Banyan Biomarkers Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avacta Group PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Geno Technology Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anavex Life Sciences Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alseres Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aposense Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations